This study aimed to assess understanding of antibiotic resistance and evaluate antibiotic use themes among the general public. In March 2018, respondents that were ≥21 years old and residing in the United States were recruited from ResearchMatch.org and surveyed to collect data on respondent expectations, knowledge, and opinions regarding prescribing antibiotics and antibiotic resistance. Content analysis was used to code open-ended definitions of antibiotic resistance into central themes. Chi-square tests were used to assess differences between the definitions of antibiotic resistance and antibiotic use. Among the 657 respondents, nearly all (99%) had taken an antibiotic previously. When asked to define antibiotic resistance, the definitions provided were inductively coded into six central themes: 35% bacteria adaptation, 22% misuse/overuse, 22% resistant bacteria, 10% antibiotic ineffectiveness, 7% body immunity, and 3% provided an incorrect definition with no consistent theme. Themes that were identified in respondent definitions of resistance significantly differed between those who reported having shared an antibiotic versus those who had not (p = 0.03). Public health campaigns remain a central component in the fight to combat antibiotic resistance. Future campaigns should address the public’s understanding of antibiotic resistance and modifiable behaviors that may contribute to resistance.
People who use drugs (PWUD) are increasingly acquiring and transmitting hepatitis C virus (HCV) and being admitted to the hospital for often costly non–HCV-related conditions. Traditionally, treatment of HCV has been deferred to the outpatient setting. However, outpatient HCV follow-up can be an arduous process to navigate with resultant gaps in care, especially for PWUD with numerous complex psychosocial and medical comorbidities. Hospitalization presents a key opportunity to initiate treatment, and several institutions have piloted inpatient treatment models with intensive outreach. We conducted a narrative review of peer-reviewed literature (2014–2024) evaluating hospital-based HCV treatment models for PWUD; 6 studies from 4 countries met inclusion criteria. Evidence suggests that engaging PWUD during hospitalization leads to higher treatment initiation and completion as compared with standard-of-care outpatient referral. Inpatient HCV treatment models should be one part of a comprehensive plan in the United States and internationally to eliminate HCV for all.
16 June 2025 in Antimicrobial Stewardship & Healthcare Epidemiology
Background: Approximately 95% of patients with a beta-lactam allergy noted in their medical record are not truly allergic when tested. These patients may unnecessarily avoid first-line antibiotics, resulting in increased treatment failure, higher costs, and antibiotic resistance. Bone marrow transplant (BMT) patients may be at higher risk for these adverse outcomes due to weakened immune systems and high risk for severe infections. Our objective was to evaluate beta-lactam allergy labels and their influence on BMT patient outcomes. Methods: We conducted a retrospective cohort study of adult inpatients undergoing BMT during April 2018-March 2020. Eligibility for penicillin allergy testing/de-labeling was evaluated. Multivariable logistic regression was performed to measure independent effects of beta-lactam allergy labels on 100-day outcomes: mortality, ICU admission, rehospitalization, and intravenous antibiotic use. Results: Among 358 BMT patients, 75 (21%) had a beta-lactam allergy label at baseline. Mortality was higher in patients with an allergy label (14.7% vs 7.8%, P = 0.067). In multivariable analysis, patients with allergy labels were not at a significantly greater risk of mortality (OR = 1.60; 95% CI = 0.68 – 3.78) but were significantly more likely to receive carbapenems (OR = 6.27; 95% CI = 2.81–13.98). All patients with penicillin-class allergy labels were eligible for allergy testing/de-labeling. Conclusion: We did not observe a significant increased risk of mortality in BMT patients with beta-lactam allergy labels; however, increased carbapenem use was observed. Penicillin allergy de-labeling programs may help optimize antibiotic prescribing in BMT patients. Larger studies are needed to quantify the impact of beta-lactam allergy labels on BMT patient outcomes.
In 169 hospitalized adults with penicillin allergy histories, either through interview or listed in the electronic medical record of urticaria, angioedema, anaphylaxis, and/or shortness of breath at least 10 years ago, 94.1% tolerated a direct oral amoxicillin challenge led by a non-allergy specialist and were delabeled. Mild reactions occurred in 5.9%, with no severe events. This safe, effective approach may improve antibiotic stewardship, reduce costs, and support broader implementation over penicillin skin testing.
25 June 2024 in The Primary Care Companion For CNS Disorders
This report discusses utilization of a 3-times-daily prazosin dosing scheme during a hospital admission for a patient experiencing severe nightmares and daytime flashbacks associated with PTSD.